Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

On Tuesday, based on data from those with estrogen receptor 1 (ESR1m) mutations, the duo said that the protein degrader reached the primary endpoint in their Phase 3 VERITAC-2 trial designed to ...

Wedbush became the latest brokerage to downgrade Arvinas (NASDAQ:ARVN) on Wednesday after the company posted underwhelming ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

Wedbush downgraded Arvinas (ARVN) to Neutral from Outperform with a price target of $12, down from $57.Optimize Your Investment Research with ...